Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Carbone

Showing results (561-570 of 651) with videos related to

Pageof 66
Sort By:
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2012
Added value of a serum proteomic signature in the diagnostic evaluation of lung nodulesChad V Pecot, Ming Li, Xueqiong J Zhang, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Rejuvenation of white adipose tissue in a longitudinal heterochronic transplantation modelAlibek Moldakozhayev, Alexander Tyshkovskiy, Pasquale Nigro, et al.
Science Translational Medicine|January 10, 2020
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-βAlessandra Metelli, Bill X Wu, Brian Riesenberg, et al.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Cancer Research|January 25, 2005
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancerJoseph Amann, Shailaja Kalyankrishna, Pierre P Massion, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2010
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancerHoward H Bailey, KyungMann Kim, Ajit K Verma, et al.
Nature Immunology|October 20, 2022
SUSD2 suppresses CD8<sup>+</sup> T cell antitumor immunity by targeting IL-2 receptor signalingBao Zhao, Weipeng Gong, Anjun Ma, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Journal of the National Cancer Institute|November 19, 2015
PDL1 Regulation by p53 via miR-34Maria Angelica Cortez, Cristina Ivan, David Valdecanas, et al.
Pageof 66

Showing results (561-570 of 651) with videos related to

Sort By:
Pageof 66
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 1, 2012
Added value of a serum proteomic signature in the diagnostic evaluation of lung nodulesChad V Pecot, Ming Li, Xueqiong J Zhang, et al.
Biorxiv : the Preprint Server for Biology|January 9, 2026
Rejuvenation of white adipose tissue in a longitudinal heterochronic transplantation modelAlibek Moldakozhayev, Alexander Tyshkovskiy, Pasquale Nigro, et al.
Science Translational Medicine|January 10, 2020
Thrombin contributes to cancer immune evasion via proteolysis of platelet-bound GARP to activate LTGF-βAlessandra Metelli, Bill X Wu, Brian Riesenberg, et al.
The Lancet. Oncology|November 10, 2016
Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trialJoel W Neal, Suzanne E Dahlberg, Heather A Wakelee, et al.
Cancer Research|January 25, 2005
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancerJoseph Amann, Shailaja Kalyankrishna, Pierre P Massion, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 7, 2010
A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancerHoward H Bailey, KyungMann Kim, Ajit K Verma, et al.
Nature Immunology|October 20, 2022
SUSD2 suppresses CD8<sup>+</sup> T cell antitumor immunity by targeting IL-2 receptor signalingBao Zhao, Weipeng Gong, Anjun Ma, et al.
Clinical Lung Cancer|August 19, 2020
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508)Jyoti D Patel, Ju-Whei Lee, David P Carbone, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2006
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancerMichael P Fanucchi, Frank V Fossella, Robert Belt, et al.
Journal of the National Cancer Institute|November 19, 2015
PDL1 Regulation by p53 via miR-34Maria Angelica Cortez, Cristina Ivan, David Valdecanas, et al.
Pageof 66